FDA Clears Software for Enhancing CCTA Assessment of Atherosclerosis
Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.
The Food and Drug Administration (FDA) has granted 510(k) clearance for PlaqueIQ™, an emerging software that may enhance quantification of arterial plaque buildup shown on coronary computed tomography angiography (CCTA) imaging.
Employing image restoration algorithms to reduce motion and calcium blooming artifacts, the Plaque IQ software creates 3D modelling of coronary arteries via data segmentation and subsequently provides quantified assessment of tissue composition and structure, according to Elucid, the developer of PlaqueIQ.
Offering an interactive visualization of coronary anatomy and plaque quantification on multiple views, the PlaqueID software recently garnered 510(k) clearance from the Food and Drug Administration (FDA). (Images courtesy of Elucid.)
Emphasizing that approximately half of the United State population between 45 to 84 years of age have atherosclerosis without symptomatic presentations, Elucid maintained that PlaqueIQ may facilitate enhanced visualization and characterization of arterial plaque, and prevention of major adverse cardiovascular events.
“It’s time to shift our focus from merely estimating risk and treating risk of MI to directly visualizing and treating the disease itself by looking at the coronary arteries,” maintained Amir Ahmadi, M.D., an associate professor of medicine and cardiology at the Icahn School of Medicine at Mount Sinai in New York, N.Y. “I believe that PlaqueIQ will enable physicians to better ‘see’ the disease — specifically plaque quantity and type — so that we can treat patients with greater precision and in (a) personalized manner, improve their quality of life, and ultimately prevent (myocardial infarction) and stroke more effectively.”
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI Assessment of Ischemic Core Volume on CT with Brainomix 360 Platform
April 8th 2025For patients with acute ischemic stroke, research has demonstrated that automated assessment of ischemic core volume on brain CT scans via the Brainomix 360 software is equivalent to that derived from CT perfusion.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
